

## FORM 7

### MONTHLY PROGRESS REPORT – January 2015

**Name of CNSX Issuer:** Pivotal Therapeutics Inc. (the "Issuer").

**Trading Symbol:** PVO

**Number of Outstanding Listed Securities:** 93,469,236 common shares

**Date:** February 11, 2015

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by the CNSX Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the CNSX.ca website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the CNSX Policies. The discussion in this report must be factual, balanced and non-promotional.

#### **General Instructions**

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

## Report on Business

1. **Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.**

Over the previous month, the Issuer's business activities have been focused on continuing the commercialization of its lead products **VASCAZEN**<sup>®</sup>, **OMAZEN**<sup>®</sup> and a new product **BeneFishial**<sup>™</sup>. **VASCAZEN**<sup>®</sup> is a prescription-only medical food for the dietary management of an Omega-3 deficiency in patients with cardiovascular disease. The product is readily available for sale through a prescription in all major pharmacies across the U.S. **OMAZEN**<sup>®</sup> is Pivotal's second product to market for the maintenance of good health, contains greater than 90% pure pharmaceutical grade Omega-3 with the optimal 6:1 ratio of EPA to DHA. **OMAZEN**<sup>®</sup> is available for sale and distribution in Canada only and is positioned for the professional OTC market. **BeneFishial**<sup>™</sup> is the first product in Pivotal's new nutraceutical product line, which has been specifically designed to be sold in the OTC direct to retail or direct to consumer markets.

During the month, the CEO Mr. Eugene Bortoluzzi provided in a Press Release a summary of the Company's accomplishments in 2014 and its outlook for 2015. Also, during the month the Company announced that it had received the final and unrestricted authorization from the Agence Nationale de la Sécurité du Médicament - French National Agency for Drug Safety to conduct a Phase IIa clinical trial with its **PVT-100** drug candidate. **PVT-100** uses **VASCAZEN**<sup>®</sup>'s proprietary formulation for the stabilization of vulnerable plaque in patients undergoing carotid endarterectomy, a surgical procedure to remove material accumulated in the arteries to reduce the risk of stroke.

The **VASCAZEN**<sup>®</sup> **POMEGA** Phase IIa clinical trial is a double-blinded placebo controlled study in over 100 patients scheduled to undergo vascular invasive surgery for carotid endarterectomy at the University Hospital of Strasbourg, France. Patients shall be randomized to receive either Pivotal's uniquely formulated drug candidate **PVT-100** or a placebo, for six consecutive weeks. The composite primary endpoint of the trial consists of histomorphological, biochemical and immunological status of the vascular plaque.

2. **Provide a general overview and discussion of the activities of management.**

Management is continuing to work and deliver on the objectives laid out in the business plan to grow sales of its products **VASCAZEN**<sup>®</sup>, **OMAZEN**<sup>®</sup> and **BeneFishial**<sup>™</sup> and to develop a rapid format point-of-care (POC) test to identify Omega-3 deficient patients to increase shareholder value.

Additionally, management continues to build relationships in the business community in which it operates.

- 3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.**

This item is not applicable to the Issuer for the month of January 2015.

- 4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.**

This item is not applicable to the Issuer for the month of January 2015.

- 5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of.**

This item is not applicable to the Issuer for the month of January 2015.

- 6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.**

This item is not applicable to the Issuer for the month of January 2015.

- 7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.**

This item is not applicable to the Issuer for the month of January 2015.

**8. Describe the acquisition of new customers or loss of customers.**

This item is not applicable to the Issuer for the month of January 2015.

**9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.**

This item is not applicable to the Issuer for the month of January 2015.

**10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.**

This item is not applicable to the Issuer for the month of January 2015.

**11. Report on any labour disputes and resolutions of those disputes if applicable.**

This item is not applicable to the Issuer.

**12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.**

This item is not applicable to the Issuer.

**13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.**

This item is not applicable to the Issuer for the month of January 2015.

**14. Provide details of any securities issued and options or warrants granted.**

This item is not applicable to the Issuer for the month of January 2015.

**15. Provide details of any loans to or by Related Persons.**

This item is not applicable to the Issuer for the month of January 2015.

**16. Provide details of any changes in directors, officers or committee members.**

This item is not applicable to the Issuer for the month of January 2015.

**17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.**

None.

## Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1)
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: February 11, 2015

Rachelle MacSweeney  
Name of Director or Senior  
Officer

“Rachelle MacSweeney”  
Signature

President, Chief Operating  
Officer and Director  
Official Capacity

<b><i>Issuer Details</i></b> <u>Name of Issuer</u> Pivotal Therapeutics Inc.	<u>For Month End</u> January 31, 2015	<u>Date of Report</u> (YY/MM/D) 15/02/11
<u>Issuer Address</u> 81 Zenway Blvd., Unit 10		
<u>City/Province/Postal Code</u> Woodbridge, Ontario L4H 0S5	<u>Issuer Fax No.</u> (905) 856-2177	<u>Issuer Telephone No.</u> (905) 856-9797
<u>Contact Name</u> Rachelle MacSweeney	<u>Contact Position</u> President, Chief Operating Officer & Director	<u>Contact Telephone No.</u> (905) 856-9797
<u>Contact Email Address</u> rmacsweeney@pivotaltherapeutics.us	<u>Web Site Address</u> <a href="http://www.pivotaltherapeutics.us">www.pivotaltherapeutics.us</a>	